We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Diurnal Group Plc | LSE:DNL | London | Ordinary Share | GB00BDB6Q760 | ORD GBP0.05 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 27.30 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
Date | Subject | Author | Discuss |
---|---|---|---|
27/1/2021 08:11 | Shrewdie, it's Q1 for EU approval (massive milestone and major derisking of Chronocort getting approved globally $2.5bln market opportunity) | trotterstrading | |
27/1/2021 08:09 | Managed to get a few k extra on the bell | trotterstrading | |
27/1/2021 08:08 | Good luck buying in today if you sold hahaha | aimmafia | |
27/1/2021 08:01 | Cracking news.....should hopefully be a great year of news flow for DNL....DYOR, let's hope market starts looking to the future and valuing DNL properly! DYOR | qs99 | |
27/1/2021 07:58 | Looking to add more first thing on that news | tburns | |
27/1/2021 07:55 | Quick maths,Chinese population (2021 estimate) 1,439,323,776 รท 6084 (It is estimated that congenital adrenal hyperplasia (CAH) occurs in 1 in 6,084 births in China) = 236,575 CAH patients.That is a vast combined market potential for "Alkindi" and "Chronocort" (for which there is no agreement as yet in China for Chronocort). | affc21 | |
27/1/2021 07:48 | yes and like its been said you would think all these partners are ready made to just repeat with chronocort. whats the timings for chronocort again? | shrewdmole | |
27/1/2021 07:44 | Surely a formality with FDA and EU/UK | trotterstrading | |
27/1/2021 07:29 | No competition in China and another ready partner for Chrono. if granted.Simmering nicely. - Gla. | geraldus | |
27/1/2021 07:19 | Slowly building an empire. | royalalbert | |
27/1/2021 07:18 | EV is even lower at £56m... | affc21 | |
27/1/2021 07:16 | Now that is good news considering the vast market potential in China for Alkindi, just needs to get regulartory clearance | affc21 | |
27/1/2021 07:12 | Another tick in the box albeit small upfront but long term reasonable Milestones and decent royalties so long term a potentially rewarding deal to add to the worldwide growing list. Worth mention you would imagine that if Chronocort receives EMA acceptance then it will be Rinse and repeat with all the worldwide partners so excitement ahead. 76Mcap crazy | best1467 | |
27/1/2021 07:07 | Excellent bit of news. | simon_64 | |
26/1/2021 13:39 | Seen one analyst target at $15 | l0ngterm | |
26/1/2021 13:27 | Eaton up again nearly 10 dollars ! | s34icknote | |
26/1/2021 12:19 | Interesting timing, if it lands on the 23rd. | l0ngterm | |
26/1/2021 08:45 | Trading update on 23rd Feb, may give us some direction. | dandu69 | |
25/1/2021 21:26 | Quite simply the lacklustre share price is down to a disappointing update coupled with a lack of sales info. On a more positive note, the building blocks are being put in place so I would expect a much improved picture by the summer. | mufprat | |
25/1/2021 11:01 | It does look like the bottom is around 50 p and a strong rebound expected | tialouise | |
25/1/2021 10:21 | Is the seller forcing it down for a double-bottom around 50p again? Sigh. More patience needed, but the key thing is that the positive story hasn't changed! | cyberbub | |
25/1/2021 10:14 | Our 10k seller is busy! | trotterstrading | |
22/1/2021 16:27 | Blue finish would have been nice ;) | mikeh30 | |
22/1/2021 16:16 | Last few days they have dropped the bid, picked up shares and then ended the day not far off level....DYOR, but looking forward to the +ve news and take MMs stocking up as a good sign | qs99 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions